Literature DB >> 34709441

Clinical, Biochemical, Radiological, Genetic and Therapeutic Analysis of Patients with COMP Gene Variants.

Hanting Liang1, Yanfang Hou1, Qianqian Pang1, Yan Jiang1, Ou Wang1, Mei Li1, Xiaoping Xing1, Huijuan Zhu1, Weibo Xia2.   

Abstract

Pseudoachondroplasia (PSACH) and multiple epiphyseal dysplasia type 1 (MED1) are two rare skeletal disorders caused by cartilage oligomeric matrix protein (COMP) variants. This study aims to analyze the genotype and phenotype of patients with COMP variants. Clinical information for 14 probands was collected; DNA was extracted from blood for COMP variant detection. Clinical manifestations and radiology scoring systems were established to evaluate the severity of each patient's condition. Serum COMP levels in PSACH patients and healthy subjects were measured. Thirty-nine patients were included, along with 12 PSACH probands and two MED1 probands. Disproportionate short stature, waddling gait, early-onset osteoarthritis and skeletal deformities were the most common features. The height Z-score of PSACH patients correlated negatively with age at evaluation (r =  - 0.603, p = 0.01) and the clinical manifestation score (r =  - 0.556, p = 0.039). Over 50% of the PSACH patients were overweight/obese. The median serum COMP level in PSACH patients was 16.75 ng/ml, which was significantly lower than that in healthy controls (98.53 ng/ml; p < 0.001). The condition of MED1 patients was better than that of PSACH patients. Four novel variants of COMP were detected: c.874T>C, c.1123_1134del, c.1531G>A, and c.1576G>T. Height Z-scores and serum COMP levels were significantly lower in patients carrying mutations located in calmodulin-like domains 6, 7, and 8. As the two phenotypes overlap to different degrees, PSACH and MED1 are suggested to combine to produce "spondyloepiphyseal dysplasia, COMP type". Clinical manifestations and radiology scoring systems, serum COMP levels and genotype are important for evaluating patient condition severity.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  COMP; Multiple epiphyseal dysplasia type 1; Pseudoachondroplasia; Serum; Spondyloepiphyseal dysplasia, COMP type

Mesh:

Substances:

Year:  2021        PMID: 34709441     DOI: 10.1007/s00223-021-00920-6

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  31 in total

1.  Cartilage oligomeric matrix protein/thrombospondin 5 supports chondrocyte attachment through interaction with integrins.

Authors:  Faye Hui Chen; Ashby O Thomas; Jacqueline T Hecht; Mary B Goldring; Jack Lawler
Journal:  J Biol Chem       Date:  2005-07-28       Impact factor: 5.157

2.  Disease-causing mutations in cartilage oligomeric matrix protein cause an unstructured Ca2+ binding domain.

Authors:  Quinn Kleerekoper; Jacqueline T Hecht; John A Putkey
Journal:  J Biol Chem       Date:  2002-01-08       Impact factor: 5.157

3.  Mutations in cartilage oligomeric matrix protein causing pseudoachondroplasia and multiple epiphyseal dysplasia affect binding of calcium and collagen I, II, and IX.

Authors:  J Thur; K Rosenberg; D P Nitsche; T Pihlajamaa; L Ala-Kokko; D Heinegård; M Paulsson; P Maurer
Journal:  J Biol Chem       Date:  2000-11-17       Impact factor: 5.157

4.  Characterization of human and mouse cartilage oligomeric matrix protein.

Authors:  G Newton; S Weremowicz; C C Morton; N G Copeland; D J Gilbert; N A Jenkins; J Lawler
Journal:  Genomics       Date:  1994-12       Impact factor: 5.736

Review 5.  Role of TSP-5/COMP in pseudoachondroplasia.

Authors:  Karen L Posey; Elizabeth Hayes; Richard Haynes; Jacqueline T Hecht
Journal:  Int J Biochem Cell Biol       Date:  2004-06       Impact factor: 5.085

6.  Interaction of cartilage oligomeric matrix protein/thrombospondin 5 with aggrecan.

Authors:  Faye Hui Chen; Mary E Herndon; Nichlesh Patel; Jacqueline T Hecht; Rocky S Tuan; Jack Lawler
Journal:  J Biol Chem       Date:  2007-06-22       Impact factor: 5.157

7.  Pseudoachondroplasia and multiple epiphyseal dysplasia due to mutations in the cartilage oligomeric matrix protein gene.

Authors:  M D Briggs; S M Hoffman; L M King; A S Olsen; H Mohrenweiser; J G Leroy; G R Mortier; D L Rimoin; R S Lachman; E S Gaines
Journal:  Nat Genet       Date:  1995-07       Impact factor: 38.330

8.  Mutations in exon 17B of cartilage oligomeric matrix protein (COMP) cause pseudoachondroplasia.

Authors:  J T Hecht; L D Nelson; E Crowder; Y Wang; F F Elder; W R Harrison; C A Francomano; C K Prange; G G Lennon; M Deere
Journal:  Nat Genet       Date:  1995-07       Impact factor: 38.330

Review 9.  Multiple epiphyseal dysplasia: clinical and radiographic features, differential diagnosis and molecular basis.

Authors:  Sheila Unger; Luisa Bonafé; Andrea Superti-Furga
Journal:  Best Pract Res Clin Rheumatol       Date:  2008-03       Impact factor: 4.098

10.  Genotype to phenotype correlations in cartilage oligomeric matrix protein associated chondrodysplasias.

Authors:  Michael D Briggs; Joanne Brock; Simon C Ramsden; Peter A Bell
Journal:  Eur J Hum Genet       Date:  2014-03-05       Impact factor: 4.246

View more
  2 in total

1.  Exploring and expanding the phenotype and genotype diversity in seven Chinese families with spondylo-epi-metaphyseal dysplasia.

Authors:  Shanshan Lv; Jiao Zhao; Li Liu; Chun Wang; Hua Yue; Hao Zhang; Shanshan Li; Zhenlin Zhang
Journal:  Front Genet       Date:  2022-08-31       Impact factor: 4.772

Review 2.  Cartilage Oligomeric Matrix Protein, Diseases, and Therapeutic Opportunities.

Authors:  Jiarui Cui; Jiaming Zhang
Journal:  Int J Mol Sci       Date:  2022-08-17       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.